Results 51 to 60 of about 29,210 (297)

A novel patient-derived 3D model recapitulates mantle cell lymphoma lymph node signaling, immune profile and in vivo ibrutinib responses

Leukemia, 2023
Mantle cell lymphoma (MCL), a rare and aggressive B-cell non-Hodgkin lymphoma, mainly develops in the lymph node (LN) and creates a protective and immunosuppressive niche that facilitates tumor survival, proliferation and chemoresistance.
F. Araujo-Ayala, Cèlia Dobaño-López, J. G. Valero, F. Nadeu, F. Gava, Carla Faria, Marine Norlund, R. Morin, Pascale Bernes-Lasserre, N. Serrat, Heribert Playa-Albinyana, Rubén Giménez, E. Campo, J. Lagarde, A. López-Guillermo, E. Giné, D. Colomer, C. Bezombes, P. Pérez-Galán   +18 more
semanticscholar   +1 more source

Cardiovascular Toxicities Associated With Ibrutinib

Journal of the American College of Cardiology, 2019
Ibrutinib has revolutionized treatment for several B-cell malignancies. However, a recent clinical trial where ibrutinib was used in a front-line setting showed increased mortality during treatment compared with conventional chemotherapy. Cardiovascular toxicities were suspected as the culprit but not directly assessed in the study.The purpose of this ...
Salem, Joe-Elie, Manouchehri, Ali, Bretagne, Marie, Lebrun-Vignes, Bénédicte, Groarke, John, Johnson, Douglas, Yang, Tao, Reddy, Nishitha, Funck-Brentano, Christian, Brown, Jennifer, Roden, Dan, Moslehi, Javid   +11 more
openaire   +5 more sources

Cardiovascular Magnetic Resonance Imaging in Patients With Ibrutinib-Associated Cardiotoxicity.

JAMA Oncology, 2023
Importance Ibrutinib has been associated with serious cardiotoxic arrhythmias. In preclinical models, these events are paralleled or proceeded by diffuse myocardial injury (inflammation and fibrosis).
B. Buck, Aaron P Chum, Mitkumar Patel, R. Carter, Haseeb Nawaz, V. Yildiz, P. Ruz, Tracy E. Wiczer, K. Rogers, F. Awan, S. Bhat, A. Guha, A. Kittai, O. Simonetti, S. Raman, Grant M. Wallace, Reynaldo Sanchez, Janice M. Bonsu, J. Gambril, D. Haddad, James Mann, Lai Wei, Onaopepo Kola-Kehinde, J. Byrd, J. Woyach, D. Addison   +25 more
semanticscholar   +1 more source

First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial

Haematologica, 2022
iLLUMINATE is a randomized, open-label phase III study of ibrutinib plus obinutuzumab (n=113) versus chlorambucil plus obinutuzumab (n=116) as first-line therapy for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
C. Moreno, R. Greil, F. Demirkan, A. Tedeschi, B. Anz, L. Larratt, M. Šimkovič, J. Novák, V. Strugov, D. Gill, J. Gribben, Kevin Kwei, S. Dai, E. Hsu, J. Dean, I. Flinn   +15 more
semanticscholar   +1 more source

Ibrutinib directly reduces CD8+T cell exhaustion independent of BTK

Frontiers in Immunology, 2023
IntroductionCytotoxic CD8+ T cell (CTL) exhaustion is a dysfunctional state of T cells triggered by persistent antigen stimulation, with the characteristics of increased inhibitory receptors, impaired cytokine production and a distinct transcriptional ...
Ling Li, Manzhi Zhao, Caoimhe H. Kiernan, Melisa D. Castro Eiro, Marjan van Meurs, Inge Brouwers-Haspels, Merel E. P. Wilmsen, Dwin G. B. Grashof, Harmen J. G. van de Werken, Harmen J. G. van de Werken, Rudi W. Hendriks, Yvonne M. Mueller, Peter D. Katsikis   +12 more
doaj   +1 more source

Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.

New England Journal of Medicine, 2019
BACKGROUND Data regarding the efficacy of treatment with ibrutinib-rituximab, as compared with standard chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab, in patients with previously untreated chronic lymphocytic leukemia (CLL) have ...
T. Shanafelt, X. V. Wang, N. Kay, C. Hanson, S. O'brien, J. Barrientos, D. Jelinek, E. Braggio, J. Leis, C. C. Zhang, S. Coutre, P. Barr, A. Cashen, A. Mato, Avina K Singh, M. Mullane, R. Little, H. Erba, R. Stone, M. Litzow, M. Tallman   +20 more
semanticscholar   +1 more source

Ibrutinib: coming of age? [PDF]

Blood, 2018
In this issue of Blood, O’Brien et al report long-term efficacy and safety of ibrutinib in the first cohort of patients with chronic lymphocytic leukemia (CLL) treated, now with 5-year follow-up, the longest of any CLL cohort to date ...
openaire   +3 more sources

Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia

Blood Advances
Key Points • Patients with Waldenström macroglobulinemia and mutations in CXCR4 or TP53 had poorer prognosis after treatment with BTKis.• Patients with CXCR4 or TP53 mutations had more favorable outcomes when treated with zanubrutinib vs ibrutinib.
C. Tam, Stephen Samuel Opat, S. D'Sa, Wojciech Jurczak, Hui-Peng Lee, G. Cull, R. Owen, P. Marlton, B. Wahlin, R. García-Sanz, Helen McCarthy, Stephen P Mulligan, A. Tedeschi, J. J. Castillo, Jaroslaw Czyz, C. Fernández de Larrea, D. Belada, Edward N. Libby, J. Matous, M. Motta, Tanya Siddiqi, M. Tani, M. Trněný, Monique C. Minnema, Christian Buske, V. Leblond, S. Treon, J. Trotman, Binghao Wu, Yiling Yu, Zhirong Shen, Wai Y. Chan, J. Schneider, H. Allewelt, A. Cohen, M. Dimopoulos   +35 more
semanticscholar   +1 more source

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL

New England Journal of Medicine, 2018
BACKGROUND Ibrutinib has been approved by the Food and Drug Administration for the treatment of patients with untreated chronic lymphocytic leukemia (CLL) since 2016 but has not been compared with chemoimmunotherapy.
J. Woyach, A. Ruppert, N. Heerema, Weiqiang Zhao, Allison M. Booth, W. Ding, N. Bartlett, D. Brander, P. Barr, K. Rogers, S. Parikh, S. Coutre, A. Hurria, Jennifer R. Brown, G. Lozanski, J. Blachly, H. Ozer, Brittny T Major-Elechi, B. Fruth, S. Nattam, R. Larson, H. Erba, M. Litzow, C. Owen, C. Kuzma, J. Abramson, R. Little, Scott E. Smith, R. Stone, S. Mandrekar, J. Byrd   +30 more
semanticscholar   +1 more source

Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma

Blood Advances, 2023
Key Points • SELENE is a phase 3, placebo-controlled trial evaluating ibrutinib or placebo added to BR/R-CHOP for patients with R/R FL or MZL.• The addition of ibrutinib to BR or R-CHOP did not significantly improve the PFS.
L. Nastoupil, G. Hess, M. Pavlovsky, I. Danielewicz, Jane A Freeman, A. M. Martin Garcia-Sancho, Valeria Glazunova, Andrew A Grigg, Jing-Zhou Hou, A. Janssens, Seok-Jin Kim, Z. Masliak, P. McKay, F. Merli, W. Munakata, H. Nagai, M. Özcan, M. Preis, Tingyu Wang, Melissa Rowe, M. Tamegnon, Rui Qin, T. Henninger, M. Curtis, D. B. Caces, C. Thieblemont, G. Salles   +26 more
semanticscholar   +1 more source